Fewer than a tenth of individuals who could benefit from weight-loss injections such as Wegovy can access them, states the WHO as it issues its first advice on the therapies.
With in excess of 1,000,000,000 individuals worldwide currently obese, it is calling for increased and just availability to these injectable treatments.
According to projections, in excess of 2,000,000,000 will be obese by 2030 if no action is taken.
"Our latest guidance recognises that excess weight is a chronic disease that can be managed with comprehensive and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
Substantial prices, limited production capacity, and logistical bottlenecks are key hurdles to universal access to the injections that can aid individuals in losing considerable body mass, notes the agency.
Skinny Jab Scarcity
Despite the current most favorable outlook, the manufacturing of such drugs might only reach around 100 million people – fewer than 10% of the global need, according to the health organization.
The recommendation urges nations and manufacturers to increase availability, through strategies including licensing agreements.
A patent on semaglutide – the core ingredient of the drug Wegovy – is set to lapse in multiple nations in 2026.
The Way Obesity Jabs Work
The injections imitate a body's own hormone to slow digestion, suppress the appetite and boost satiety so individuals eat less.
Individuals commonly begin shedding pounds after several weeks of starting on the regular doses.
Evidence points to people may regain a significant portion a year later of discontinuing the drug, because their typical appetite come back.
To be above a healthy weight elevates your chance for experiencing diseases, like diabetes, heart disease, brain attack, and some cancers.
Obesity impacts people in all nations and was linked to over three and a half million fatalities worldwide in 2024, according to the WHO.
